Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor.

Spleen tyrosine kinase (Syk), a key mediator of immunoreceptor signaling in inflammatory cells, is essential for immune complex-mediated signal transduction initiated by activated receptors for immunoglobulin G. In collagen-induced arthritis, R788/R406, a novel and potent small molecule Syk inhibitor suppressed clinical arthritis, bone erosions, pannus formation, and synovitis. Serum anti-collagen type II antibody levels were unaltered, while the half-life of exogenous antibody was extended when co-administered with R406. Expression of the targeted kinase (Syk) in synovial tissue correlated with the joint level of inflammatory cell infiltrates and was virtually undetectable in treated rats. Syk inhibition suppressed synovial cytokines and cartilage oligomeric matrix protein (COMP) in serum, suggesting a sensitive and reliable biomarker for R406 activity. These results highlight the role of activating Fcgamma receptors in inflammatory synovitis and suggest that interruption of the signaling cascade with a novel Syk inhibitor may be a useful addition to immunosuppressive disease-modifying anti-rheumatic drugs currently used in the treatment of human autoimmune diseases such as rheumatoid arthritis.

[1]  J. Ravetch,et al.  Fcgamma receptors: old friends and new family members. , 2006, Immunity.

[2]  P. V. van Riel,et al.  Fc gamma receptor mediated modulation of dendritic cells as a potential strategy in the battle against rheumatoid arthritis. , 2006, The Netherlands journal of medicine.

[3]  L. Joosten,et al.  Interleukin-18 promotes joint inflammation and induces interleukin-1-driven cartilage destruction. , 2004, The American journal of pathology.

[4]  V. Strand,et al.  Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. , 2000, Arthritis and rheumatism.

[5]  B. Aggarwal,et al.  TNF Activates Syk Protein Tyrosine Kinase Leading to TNF-Induced MAPK Activation, NF-κB Activation, and Apoptosis1 , 2004, The Journal of Immunology.

[6]  A. DeFranco,et al.  A Critical Role for Syk in Signal Transduction and Phagocytosis Mediated by Fcγ Receptors on Macrophages , 1997, The Journal of experimental medicine.

[7]  X. Ding,et al.  Altered pattern of TCR/CD3-mediated protein-tyrosyl phosphorylation in T cells from patients with systemic lupus erythematosus. Deficient expression of the T cell receptor zeta chain. , 1998, The Journal of clinical investigation.

[8]  H. Ishikawa,et al.  Electron microscopic demonstration of immunoglobulin deposition in rheumatoid cartilage. , 1975, Arthritis and rheumatism.

[9]  M. Corr,et al.  The Role of FcγR Signaling in the K/B × N Serum Transfer Model of Arthritis1 , 2002, The Journal of Immunology.

[10]  D. Payan,et al.  Targeting Syk as a treatment for allergic and autoimmune disorders , 2004, Expert opinion on investigational drugs.

[11]  R N Maini,et al.  Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. , 2000, The New England journal of medicine.

[12]  M. Lotz,et al.  IL-18 is produced by articular chondrocytes and induces proinflammatory and catabolic responses. , 1999, Journal of immunology.

[13]  D. Piwnica-Worms,et al.  Permeation Peptide Conjugates for In Vivo Molecular Imaging Applications , 2006, Molecular imaging.

[14]  R. Eisenberg,et al.  B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus , 2006, Nature Clinical Practice Rheumatology.

[15]  R. Kimberly,et al.  A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. , 1997, The Journal of clinical investigation.

[16]  M. Feldmann,et al.  Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? , 2001, Annual review of immunology.

[17]  B. Heyman,et al.  Induction and Suppression of Collagen-Induced Arthritis Is Dependent on Distinct Fcγ Receptors , 2000, The Journal of experimental medicine.

[18]  H. Dorfman,et al.  Biochemical and metabolic abnormalities in articular cartilage from osteo-arthritic human hips. II. Correlation of morphology with biochemical and metabolic data. , 1971, The Journal of bone and joint surgery. American volume.

[19]  B. Månsson,et al.  Serum concentrations of cartilage oligomeric matrix protein, fibrinogen and hyaluronan distinguish inflammation and cartilage destruction in experimental arthritis in rats. , 2002, Rheumatology.

[20]  Karen Anderson,et al.  Quantitative analysis of micro-CT imaging and histopathological signatures of experimental arthritis in rats. , 2004, Molecular imaging.

[21]  G. Firestein,et al.  Collagen induced arthritis: reversal by mercaptoethylguanidine, a novel antiinflammatory agent with a combined mechanism of action. , 1998, The Journal of rheumatology.

[22]  Stanley B. Cohen,et al.  Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. , 2002, Arthritis and rheumatism.

[23]  J. Zwerina,et al.  Mechanisms of Disease: the link between RANKL and arthritic bone disease , 2005, Nature Clinical Practice Rheumatology.

[24]  J. Smolen,et al.  Therapeutic strategies for rheumatoid arthritis , 2003, Nature Reviews Drug Discovery.

[25]  J. Bluestone,et al.  Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. , 2001, Annual review of immunology.

[26]  U. Lerner,et al.  IL-6, Leukemia Inhibitory Factor, and Oncostatin M Stimulate Bone Resorption and Regulate the Expression of Receptor Activator of NF-κB Ligand, Osteoprotegerin, and Receptor Activator of NF-κB in Mouse Calvariae1 , 2002, The Journal of Immunology.

[27]  V. Strand,et al.  The role of interleukin-1 in bone resorption in rheumatoid arthritis. , 2004, Rheumatology.

[28]  P. Emery,et al.  Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. , 2004, The New England journal of medicine.

[29]  J. Ravetch,et al.  Immunoglobulin G–mediated Inflammatory Responses Develop Normally in Complement-deficient Mice , 1996, The Journal of experimental medicine.

[30]  L. Joosten,et al.  IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation. , 1999, Journal of immunology.

[31]  C. Vedeler,et al.  Immunoglobulin G Fc-receptor (FcγR) IIA and IIIB polymorphisms related to disability in MS , 1999, Neurology.

[32]  Victor L. J. Tybulewicz,et al.  Perinatal lethality and blocked B-cell development in mice lacking the tyrosine kinase Syk , 1995, Nature.

[33]  G. Firestein,et al.  Common mechanisms in immune-mediated inflammatory disease. , 2005, The Journal of rheumatology. Supplement.

[34]  G. Firestein.  Evolving concepts of rheumatoid arthritis , 2003, Nature.

[35]  Ralph Weissleder,et al.  Arthritis critically dependent on innate immune system players. , 2002, Immunity.

[36]  M. Feldmann,et al.  Evaluation of TNF-α and IL-1 Blockade in Collagen-Induced Arthritis and Comparison with Combined Anti-TNF-α/Anti-CD4 Therapy1 , 2000, The Journal of Immunology.

[37]  F. Arnett,et al.  Fc gamma RIIA alleles are heritable risk factors for lupus nephritis in African Americans. , 1996, The Journal of clinical investigation.

[38]  H J Mankin,et al.  Biochemical and metabolic abnormalities in articular cartilage from osteo-arthritic human hips. , 1970, The Journal of bone and joint surgery. American volume.

[39]  A. Mócsai,et al.  The immunomodulatory adapter proteins DAP12 and Fc receptor γ-chain (FcRγ) regulate development of functional osteoclasts through the Syk tyrosine kinase , 2004 .

[40]  T. Kagari,et al.  Essential Role of Fcγ Receptors in Anti-Type II Collagen Antibody-Induced Arthritis , 2003, The Journal of Immunology.

[41]  P. Ricciardi-Castagnoli,et al.  A Critical Role for Syk Protein Tyrosine Kinase in Fc Receptor-Mediated Antigen Presentation and Induction of Dendritic Cell Maturation , 2003, The Journal of Immunology.

[42]  J. Barrett,et al.  Analysis of Fcγ receptor haplotypes in rheumatoid arthritis: FCGR3A remains a major susceptibility gene at this locus, with an additional contribution from FCGR3B , 2005, Arthritis research & therapy.

[43]  E. Gelfand,et al.  Inhibition of spleen tyrosine kinase prevents mast cell activation and airway hyperresponsiveness. , 2006, American journal of respiratory and critical care medicine.

[44]  R. Geha,et al.  IgG Fc receptor polymorphisms in human disease: implications for intravenous immunoglobulin therapy. , 2003, The Journal of allergy and clinical immunology.

[45]  E. Gelfand,et al.  Syk activation in dendritic cells is essential for airway hyperresponsiveness and inflammation. , 2006, American journal of respiratory cell and molecular biology.

[46]  J. Bluestone,et al.  CTLA4Ig: bridging the basic immunology with clinical application. , 2006, Immunity.

[47]  M. Dougados,et al.  Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. , 2005, The New England journal of medicine.

[48]  T. Takai.  Roles of Fc receptors in autoimmunity , 2002, Nature Reviews Immunology.

[49]  D. Heinegård,et al.  Prognostic laboratory markers of joint damage in rheumatoid arthritis , 2004, Annals of the rheumatic diseases.

[50]  I. McInnes,et al.  A Novel Dendritic Cell-Induced Model of Erosive Inflammatory Arthritis: Distinct Roles for Dendritic Cells in T Cell Activation and Induction of Local Inflammation1 , 2002, The Journal of Immunology.

[51]  B. Månsson,et al.  Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept , 2003, Arthritis research & therapy.

[52]  G. Cooper,et al.  A novel polymorphism in the Fcgamma receptor IIB (CD32B) transmembrane region alters receptor signaling. , 2003, Arthritis and rheumatism.

[53]  P. Tak,et al.  A Novel Spleen Tyrosine Kinase Inhibitor Blocks c-Jun N-Terminal Kinase-Mediated Gene Expression in Synoviocytes , 2006, Journal of Pharmacology and Experimental Therapeutics.

[54]  S. Barnum,et al.  Local production of complement proteins in rheumatoid arthritis synovium. , 2002, Arthritis and rheumatism.

[55]  J. Ravetch,et al.  A dominant role for mast cell Fc receptors in the Arthus reaction. , 1996, Immunity.

[56]  J. V. Ravetch,et al.  IgG Fc receptors. , 2001, Annual review of immunology.

[57]  V. Kouskoff,et al.  Organ-Specific Disease Provoked by Systemic Autoimmunity , 1996, Cell.

[58]  D. Payan,et al.  R406, an Orally Available Spleen Tyrosine Kinase Inhibitor Blocks Fc Receptor Signaling and Reduces Immune Complex-Mediated Inflammation , 2006, Journal of Pharmacology and Experimental Therapeutics.